Agenus Net Profit Margin 2010-2022 | AGEN
Agenus net profit margin from 2010 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Agenus Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2022-03-31 |
$0.31B |
$-0.02B |
-6.13% |
| 2021-12-31 |
$0.30B |
$-0.03B |
-8.45% |
| 2021-09-30 |
$0.31B |
$0.00B |
0.98% |
| 2021-06-30 |
$0.07B |
$-0.23B |
-327.54% |
| 2021-03-31 |
$0.09B |
$-0.19B |
-224.71% |
| 2020-12-31 |
$0.09B |
$-0.18B |
-206.82% |
| 2020-09-30 |
$0.09B |
$-0.17B |
-189.13% |
| 2020-06-30 |
$0.10B |
$-0.17B |
-174.23% |
| 2020-03-31 |
$0.09B |
$-0.17B |
-200.00% |
| 2019-12-31 |
$0.15B |
$-0.11B |
-72.19% |
| 2019-09-30 |
$0.12B |
$-0.13B |
-104.10% |
| 2019-06-30 |
$0.12B |
$-0.11B |
-99.13% |
| 2019-03-31 |
$0.12B |
$-0.09B |
-76.52% |
| 2018-12-31 |
$0.04B |
$-0.16B |
-432.43% |
| 2018-09-30 |
$0.04B |
$-0.15B |
-376.92% |
| 2018-06-30 |
$0.03B |
$-0.15B |
-520.69% |
| 2018-03-31 |
$0.02B |
$-0.16B |
-929.41% |
| 2017-12-31 |
$0.04B |
$-0.12B |
-288.10% |
| 2017-09-30 |
$0.04B |
$-0.11B |
-280.00% |
| 2017-06-30 |
$0.04B |
$-0.12B |
-282.93% |
| 2017-03-31 |
$0.04B |
$-0.11B |
-254.55% |
| 2016-12-31 |
$0.02B |
$-0.13B |
-552.17% |
| 2016-09-30 |
$0.03B |
$-0.12B |
-468.00% |
| 2016-06-30 |
$0.03B |
$-0.09B |
-317.86% |
| 2016-03-31 |
$0.03B |
$-0.10B |
-374.07% |
| 2015-12-31 |
$0.03B |
$-0.09B |
-352.00% |
| 2015-09-30 |
$0.02B |
$-0.10B |
-515.79% |
| 2015-06-30 |
$0.01B |
$-0.09B |
-664.29% |
| 2015-03-31 |
$0.01B |
$-0.06B |
-554.55% |
| 2014-12-31 |
$0.01B |
$-0.04B |
-525.00% |
| 2014-09-30 |
$0.01B |
$-0.02B |
-366.67% |
| 2014-06-30 |
$0.01B |
$-0.02B |
-420.00% |
| 2014-03-31 |
$0.00B |
$-0.02B |
-800.00% |
| 2013-12-31 |
$0.00B |
$-0.03B |
-1100.00% |
| 2013-09-30 |
$0.00B |
$-0.03B |
-825.00% |
| 2013-06-30 |
$0.00B |
$-0.03B |
-800.00% |
| 2013-03-31 |
$0.00B |
$-0.03B |
-700.00% |
| 2012-12-31 |
$0.02B |
$-0.01B |
-75.00% |
| 2012-09-30 |
$0.02B |
$-0.01B |
-75.00% |
| 2012-06-30 |
$0.02B |
$-0.01B |
-75.00% |
| 2012-03-31 |
$0.02B |
$-0.01B |
-68.75% |
| 2011-12-31 |
$0.00B |
$-0.02B |
-600.00% |
| 2011-09-30 |
$0.00B |
$-0.02B |
-525.00% |
| 2011-06-30 |
$0.00B |
$-0.02B |
-525.00% |
| 2011-03-31 |
$0.00B |
$-0.02B |
-500.00% |
| 2010-12-31 |
$0.00B |
$-0.02B |
-575.00% |
| 2010-09-30 |
$0.00B |
$-0.02B |
-450.00% |
| 2010-06-30 |
$0.00B |
$-0.02B |
-575.00% |
| 2010-03-31 |
$0.00B |
$-0.03B |
-750.00% |
| 2009-12-31 |
$0.00B |
$-0.03B |
-775.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.554B |
$0.296B |
|
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
|
